Autolus Therapeutics plc (NASDAQ:AUTL) Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. increased its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 48.5% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 386,001 shares of the company's stock after acquiring an additional 126,021 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.15% of Autolus Therapeutics worth $598,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in AUTL. Candriam S.C.A. acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth $7,500,000. AXA S.A. bought a new position in Autolus Therapeutics in the fourth quarter valued at $4,288,000. Wellington Management Group LLP raised its position in Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock worth $59,562,000 after purchasing an additional 1,125,454 shares during the period. Millennium Management LLC boosted its position in Autolus Therapeutics by 91.6% during the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock valued at $3,885,000 after buying an additional 790,437 shares during the period. Finally, BIT Capital GmbH increased its position in Autolus Therapeutics by 147.0% during the 4th quarter. BIT Capital GmbH now owns 636,979 shares of the company's stock valued at $1,497,000 after purchasing an additional 379,050 shares during the period. Institutional investors own 72.83% of the company's stock.

Analyst Ratings Changes

AUTL has been the subject of several recent analyst reports. Truist Financial decreased their price target on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 10th. Finally, Wells Fargo & Company cut their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL traded down $0.05 during midday trading on Monday, hitting $2.30. The company's stock had a trading volume of 419,201 shares, compared to its average volume of 1,540,499. The business's 50 day simple moving average is $1.47 and its 200 day simple moving average is $1.97. The company has a market cap of $610.79 million, a P/E ratio of -1.90 and a beta of 1.76. Autolus Therapeutics plc has a 12-month low of $1.11 and a 12-month high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $8.98 million for the quarter, compared to the consensus estimate of $1.59 million. On average, sell-side analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.